Business Wire

Adva Network Security launches strategic project within European collaboration to create sovereign clouds

20.3.2024 16:00:00 EET | Business Wire | Press release

Share

Adva Network Security announced today that it is launching a nationally funded project to develop cloud-optimized, secure network access technology. As part of the Important Projects of Common European Interest (IPCEI), a comprehensive funding initiative is underway to create scalable, real-time and open Next-Generation Cloud Infrastructure and Services (IPCEI-CIS) aimed at ensuring digital sovereignty. Among the 19 German companies participating, Adva Network Security is responsible for developing highly secure network access technology featuring an integrated edge cloud and software solution for robust operation. The solution will be an essential component of a European independent cloud platform, enabling the rapid processing of mission-critical and sensitive data at the network edge.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320831952/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Funded by the European Union – NextGenerationEU (Graphic: Business Wire)

“The security of mission-critical networks poses major challenges for operators: Quantum computing threatens to compromise established security mechanisms, while the push for digitization requires fast and trusted data processing at the edge of networks. Our project within IPCEI-CIS addresses both of these problems and offers very simple operation through automation,” said Wolfgang Keil, senior director of cybersecurity project management at Adva Network Security. “Leveraging our experience in quantum security, protected hosting and the operation of high-security networks, we’re developing highly secure access to the European cloud. This includes protected hosting of virtualized network functions at the edge, enabling sensitive data to be processed safely and quickly on-site before being transferred securely to the cloud.”

The TRUsted cloud connectivity for automated Endpoint SECurity (TRUE-SEC) project was launched on January 1, 2024, and will run for three years. It is funded by the Federal Ministry for Economic Affairs and Climate Protection based on a resolution of the German Bundestag and financed by the European Union. Its mission is to create an innovative solution for secure network access. Renowned for its expertise in the high-security network domain, Adva Network Security has been entrusted with developing this critical component for an end-to-end European cloud infrastructure. In collaboration with many project partners, IPCEI-CIS aims to establish a standardized, open and sustainable cloud infrastructure that ensures future-proof security for data services that are compliant with stringent regulatory requirements. The initiative marks a crucial step in advancing autonomous and sovereign cloud technology across Europe.

“Already deployed across numerous high-security networks, our technology safeguards some of the most sensitive and mission-critical data. Yet, new threat scenarios require continuous improvement. Through our participation in the IPCEI-CIS initiative, we’re making an important contribution to the sovereignty of European cloud infrastructure and services,” commented Michael Roth, GM of Adva Network Security. “The funding will enable us to expand our competence center for network security in Berlin. Our growing team of cybersecurity and network specialists is playing a vital role in driving the security – and thereby the acceptance – of cloud services through innovative and technologically sophisticated solutions. We’re proud to be able to make this contribution and honored to help shape Germany’s digital future.”

About Adva Network Security

Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuard™ security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Ulrich Kohn
t +49 30 2636969166
info@advasecurity.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye